AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Efficacy of Plasma Rich in Growth Factors (PRGF) in the Treatment of Foot Ulcers in Diabetic Patients With Peripheral Arterial Disease

RecruitingPhase 4Ages 18 Years - anyAllBiotechnology Institute IMASD
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study is a randomized clinical trial that compares the effectiveness of Plasma Rich in Growth Factors (PRGF) with conventional treatment for healing foot ulcers in diabetic patients who also have peripheral arterial disease. The goal is to assess how well PRGF promotes healing over a six-month period.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Patients aged at least 18 years * Diagnosis of type 1 or 2 diabetes * Presence of one or more ulcers below the malleoli * Ulcer size ranging from 1 to 25 cm2 * Peripheral Arterial Disease (PAD) * Meet at least 2 of the following crieria: * Absence of peripheral pulses at any level on physical examination of lower extremities * Ankle pressure of 50-90 mmHg * Finger pressure 30-70 mmHg * Ankle-branchial index (ABI) 0.5-0.9 * Finger-arm index (FIBI) 0.3-0.7 * Transcutaneous oxygen pressure (TcPO2) 30-59 mmHg * Degree of infection of the lesion on IDSA/IWGDF scale not greater than 1 * Availability of observation during the study period * Properly completed patient informed consent Exclusion Criteria: * Ulcers grade 3 or higher * Positive markers for HCV, AfHBs, HIV-I/II or TP * Diabetes mellitus with poor metabolic control (evidence of glycosylated hemoglobin \>9%) * Active systemic infection * History of cancerous or precancerous lesions in the area of intervention * On active treatment with other local treatment at the site of treatment * On active treatment with immunosuppressants and/or other drugs contraindicating blood collection * History of allergy to blood derivatives * Previous diagnosis of coagulopathies * Regular and continuous treatment (โ‰ฅ 3 months) with NSAIDs (with the exception of the use of acetylsalicilic acid) * Pregnancy or women of chilbearig age not taking effective contraceptive measures. These methods are, according to recommendations of the Clinical Trial Facilitation Group (CTFG) Contraception Working Group (CTFG) (V1.1), the following Hormonal contraception associated with ovulation inhibition, intrauterine decide (IUD), intrauterine hormone-releasing system, bilateral tubal ligation, vasectomy partner, sexual abstinence * Breastfeeding women * Treatment with monoclonal antibodies * Any inabilities to participate in the study
๐Ÿ’Š

What it tests

  • Topical application of Plasma Rich in Growth Factors (PRGF)
  • Conventional treatment (conventional treatment with adequate offloading and metabolic control, +/- antibiotic).
๐Ÿ“

Where

1 site
Hospital Universitario de Basurto.
Bilbao, Spain
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy